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ABSTRACT
The number of people who are obese and who suffer 
from type 2 diabetes is one of the most prominent 
health problems of our time. Among commonly known 
reasons we may distinguish excess of food in relation 
to how much food energy our organism really needs 
(change in life style and diet), genetic predisposition, 
endocrine disorders, and use of medicines. However, 
according to latest reports, intestinal flora plays a sig-
nificant part in aetiology of these medical conditions. 
The fact that intestinal microflora may affect body 
weight, sensitivity to insulin, metabolism of sugars 
and lipids leads to a conclusion that any change within 
intestinal microflora may be the reason for pathogen-
esis of obesity and diabetes. Moreover, any attempt 
to modify it may cause decrease or limitation of the 
intensity of the medical conditions mentioned above. 
Intestinal microbiota is now one of the most develop-
ing subjects for research. Many of the world’s medical 
projects including MetaHIT (UE and China), MicrOBES 
(France), Human Microbiome Project — HMP (USA) 
focus on research on the role of intestinal bacteria for 
people’s health. Scientists are particularity interested in 
the possibility of modification of the intestinal micro-
organisms in order to treat or prevent many conditions 
including obesity and other diseases of affluence. (Clin 
Diabetol 2016; 5, 5: 164–172)
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Microbiota — another organ  
of the human body
Human gastrointestinal tract, and particularly large 
intestine, is colonized by a number of microorganisms. 
It is estimated that total weight of these microorgan-
isms is 1.5 kg and that their genome includes 100-fold 
more genes than the genome of the human. Until re-
cently, it has been stated that the number of microbial 
cell is 10-fold higher that the number of cells in the hu-
man body. However, recent studies show that these fig-
ures are overestimated. This tightly packed ecosystem 
has metabolic potential comparable with the metabolic 
activity of the liver. The role of the microorganisms in 
the maintenance of health is enormous, and yet con-
stantly discovered. Most of the isolated microorgan-
isms (94–98%) fall into four basic groups of bacteria: 
Firmicutes (64%), Bacteroidetes (23%), Proteobacteria 
(8%) and Actinobacteria (3%). The remaining, though 
few, are very diverse taxonomically [1–3]. The number 
of bacteria and their functions differ among specific 
parts of the gastrointestinal tract and depend on many 
factors, such as environmental pH, oxygen availability 
and also the kind of food ingested. Ecosystem has many 
important functions, and therefore human organism 
could not survive without inhabiting microbes. Hence, 
microbiom is considered as another organ of human 
organism. The composition of intestinal flora is differ-
ent in every human — it is unique as a fingerprint and 
can be identified (so far imperfectly) using molecular 
tests. Importantly, conventional microbiological tests, 
consisting in in vitro cultures, are practically useless in 
intestinal flora identification. Data collected in “clone 
libraries”, DNA identification and phylogenetic trees 
only confirm the complexity of this issue [4].
Development of intestinal microflora
Foetal gastrointestinal tract is sterile, and first colo-
nization occurs at birth. Type of delivery significantly 
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influences the composition of microflora. Contact of 
the child with bacterial flora of the mother’s vagina 
and faeces as well as the presence of microorganisms 
in surrounding environment immediately after natural 
delivery or absence of bacteria after caesarean delivery 
determines the type of first acquired microorganism. In-
tensive phase of the development of bacterial colonies 
ends at the age of two [5]. In the intestines of children 
born naturally, bacteria of the phylum Bifidobacterium 
and Lactobacillus appear immediately, whereas in chil-
dren delivered by Caesarean section, these microorgan-
isms appear in the intestines after about 30 days [6]. 
Another factor affecting intestinal microflora in infants 
is the diet, i.e. the type of milk consumed. It has been 
shown that in breast-fed infants’ bacteria of the phy-
lum Bifidobacterium appear earlier than in children fed 
with synthetic milk. Bifidobacteria provide protection 
against pathogenic strains by producing acetic and lac-
tic acids. Bacterial colonization depends also on many 
other factors, including hygiene level and medication 
[6]. The study of identical twins found great similarity 
in the composition of intestinal microflora immediately 
after birth and its analogous changes throughout life, 
which confirms that the main factors responsible for 
the composition of microflora might be of genetic and 
environmental nature [7]. Considering variability of the 
microflora during lifetime, microbiological profiles of 
intestinal flora of infants and adults may be created. 
The microflora of infants is composed of four main 
groups of bacteria: Bifidobacterium, Staphylococcus, 
Streptococcus and Enterobacteriaceae, whereas intes-
tinal microflora in adults includes mainly two types of 
bacteria: Bacteroidetes and Firmicutes.
The impact of various factors on the  
composition of intestinal microflora
The study by De Filippo et al. which compared 
6-year-old children living in Africa and in West Europe 
(in the vicinity of Florence, Italy) showed that the com-
position and proportions of the microbiota depend 
on the diet. The significant fundamental difference 
reported by the authors in the conclusions was dif-
ferent proportion of Bacteroidetes versus Firmicutes 
and Proteobacteria. The researchers found that the 
intestinal flora of children from Burkina Faso in Africa, 
where the diet was low in meat and contained a lot of 
fibre, vegetables and starch, contained considerably 
more bacteria of the phylum Bacteroidetes and cor-
respondingly less bacteria of the phylum Firmicutes 
compared to children from West Europe whose diet 
contained mainly meat and was reach in animal fat 
and monosaccharides. At the same time, examina-
tions of stool samples form African children showed 
the presence of bacteria of the genera Prevotella and 
Xylanibacter, microorganisms able to produce the 
enzymes hydrolysing cellulose and xylan, as well as 
higher content of short-chain fatty acids, which are 
additional source of energy. Based on these observa-
tions, the researches have proved that the diet is closely 
related to the composition of the microflora, and that 
particular microorganisms appear in the microflora 
depending on the composition of food [8]. Differences 
in the proportions of bacteria translate into differences 
in quantity and quality of the final products of bacte-
rial metabolism — short-chain fatty acids (SCFAs). The 
above-described relationship is confirmed by a study 
of intestinal microflora in subjects on a vegetarian diet. 
The study demonstrated the decrease in the number 
and changes in the diversity of bacteria of the genus 
Clostridium and the increase in the number of Bacteroi-
detes [9]. However, researchers’ opinions are divergent 
and not all studies have found similar correlations. Ley 
et al. showed identical contents of Bacteroidetes and 
Firmicutes in obese subjects who were on high-fat 
diet and in those who had switched to a low-calorie 
diet [10]. There are also studies suggesting complete 
lack of associations between Bacteroidetes/Firmicutes 
ratio and diet or BMI [11]. However, this topic is still 
developing and requires a lot of research and analyses 
taking into account all the possible factors affecting 
the reliability of the results [12]. There are also other 
factors, besides the diet, that affect the composition 
of intestinal microflora, such as genotype, age, gender, 
and environmental conditions. The intestinal microflora 
changes with age, which has been demonstrated by 
comparing the flora of children and adults and the 
elderly [13, 14]. In newborns the most prevalent are 
the bacteria of the phylum Bifidobacterium, but during 
the life the intestinal flora undergoes dynamic changes, 
eventually forming a very complex ecosystem [7]. Com-
parison of the intestinal flora of adolescents and adults 
showed increased content of Bifidobacterium and 
Clostridium in the microflora of adolescents [20]. The 
intestinal microflora of elderly people is characterised 
by the increased number of bacteria of the phylum 
Bacteroidetes and less variety of microorganisms [16].
Functions of intestinal microbiota
Intestinal microbiota has trophic, protective and 
metabolic functions:
 — trophic function — microflora significantly in-
fluences proliferation and differentiation of co-
lonic epithelium and proliferation of endothelial 
lymphocytes. It also affects the development of 
enterocytes in small intestine. Enterocytes are 
cells responsible for absorption of substances in 
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small intestine. It has been observed that in ar-
eas with a large number of bacteria the number 
and length of intestinal villi is increased compared 
to less intensely colonized areas. This association 
confirms the hypothesis that intestinal microflora 
stimulates the maturation of enterocytes;
 — protective function — microflora forms a barrier 
against colonization by pathogenic bacteria. It 
stimulates the production of substances that in-
hibit the adhesion of pathogens to intestinal epi-
thelium. Moreover, it lowers the pH of chyme by 
the production of organic acids;
 — metabolic function — it is believed that the most 
important metabolic process is degradation of 
debris by fermentation resulting in fatty acids 
production. Additionally, microflora is involved in 
the synthesis of vitamins B and K and increases 
the bioavailability of minerals.
Microbiota functions, summarized above, are as-
sociated with both the digestive and immune systems. 
The enterotype is also responsible for the proper course 
and control of many metabolic processes, and impair-
ment of its function may lead to problems in maintain-
ing homeostasis [17]. The enterotype determines the 
products of metabolism which then have a beneficial 
or detrimental effect on human organism [18]. An-
other important role of microflora is its impact on the 
structure of the final section of the digestive tract. It 
also influences bowel motor function [16]. So, what 
composition of the flora would be most appropriate 
to preserve the balance of the metabolic processes? It 
seems that the basic criterion is the variety, because it 
affects favourably the metabolic processes.
Dysbiosis
As it has been proven above, there are many 
factors that can disturb the microflora balance and 
cause dysbiosis. The most important of these factors 
is high-fat, high-protein diet [19]. Dysbiosis may be 
also caused by some drugs, such as antibiotics, proton 
pump inhibitors (PPI), nonsteroidal anti-inflammatory 
drugs (NSAIDs), iron, methotrexate, and metformin. 
Additionally, chronic stress and gastrointestinal tract 
infections may change the proportions of two main 
phyla, Bacteroides and Firmicutes [20].
Disturbed Bacteroidetes/Firmicutes ratio is ob-
served in overweight people [17]. High-fat and low-
carbohydrate diet leads to deficiency of Bifidobacteria 
[18]. In the gastrointestinal tract of obese individuals 
the most prevalent becomes a type of Gram-positive 
bacteria, Mollicutes, which very efficiently generate 
energy from food. 
Impact of microbiota on energy  
homeostasis and fat storage
The impact of intestinal microflora on energy 
homeostasis and fat storage in host organism are 
still poorly understood. Stimulation or inhibition of 
metabolic pathways correlates with changes in the 
qualitative or quantitative composition of bacterial 
enterotype. A study on mice showed that the treatment 
with antibiotics, norfloxacin and ampicillin, caused 
changes in the composition of intestinal microflora, 
leading to improvement in fasting glycaemia, glucose 
tolerance and insulin sensitivity compared to untreated 
control group [21].
Leaky gut syndrome
Dysbiosis leads, among others, to disorders of 
the structure and function of the intestinal barrier 
resulting in a condition called “leaky gut syndrome”. 
In the future, this syndrome might prove to be the 
most important consequence of dysbiosis. Damage to 
the barrier enables the penetration into the body of 
microorganisms and their metabolites causing chronic 
inflammation. Tight junctions, gap junctions and 
desmosomes ensure the integrity of the enterocytes. 
Dysbiosis impairs the synthesis of zonulin 1 and occlu-
din (important elements of the tight junction) causing 
functional damage to the integrity of the mucosa 
and, subsequently, increasing its permeability to many 
harmful substances and antigens. Besides the SCFAs, 
also very toxic bacterial lipopolysaccharide (LPS) can 
enter the organism. This endotoxin is a component of 
the outer membrane of the cell wall of Gram-negative 
bacteria and cyanobacteria inhabiting the gastrointes-
tinal tract [22].
The development of obesity is accompanied by 
systemic inflammatory response. Inflammation is as-
sociated with the release of tumour necrosis factor 
(TNF-alpha) and IL-6 from both macrophages and adi-
pocytes. Inflammation in the intestinal mucosa causes 
a loss of intestinal barrier integrity, which increases the 
permeability of the intestinal wall to bacteria, bacterial 
lipopolysaccharide (LPS) or other bacterial particles [28].
Recently, there has been a discussion on the 
role of the intestinal barrier permeability to dietary 
proteins and the possibility of evoking the so-called 
IgG-mediated allergy, which may result in obesity and 
metabolic diseases [23]. Some studies suggest potential 
pathological effect of anti-IgG and resulting chronic 
inflammation on the development of obesity.
The intestinal microflora by synthesis and secretion 
of many chemicals may cause two-fold increase in the 
capillary density in the epithelium of the small intestine 
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resulting in higher absorption of monosaccharides 
within this part of the intestinal tract [24]. 
Intestinal bacteria synthesize glycosidic hydrolases 
— enzymes required to break down complex plant 
polysaccharides (starch, cellulose, pectin, xylan, inulin) 
contained in those products consumed that cannot be 
digested by human enzymes [25]. Thanks to symbiosis 
between human organism and intestinal bacteria, it is 
possible to obtain energy from SCFAs — compounds 
that cannot be degraded by digestive enzymes, but 
can enter the blood stream as a result of fermentation 
carried out by the microflora. It is possible to provide 
this way 80–200 calories a day, which is ~ 4–10% of 
the daily requirement of an adult [26]. Although the 
amount of energy seems insignificant, in the long 
term this can have a considerable impact on body 
weight. The main compounds generated as a result of 
the above-mentioned symbiosis are short-chain fatty 
acids (SCFAs) which include i.a. acetate, propionate 
and butyrate, wherein the acetic acid is the dominant 
type of SCFAs [27]. The only one SCFA constituting a 
source of energy for the body is propionic acid, which 
can be used in the synthesis of glucose and lipids [28].
Metabolic functions of SCFAs play significant roles 
in energy homeostasis of the body and in the develop-
ment of obesity and type 2 diabetes: they activate G 
protein-coupled receptor 41 (GPR41) by stimulating 
the secretion of peptide YY (PYY) [29]. PYY is a hor-
mone that slows intestinal transit and thus increases 
the absorption of nutrients and production of energy. 
Its influence is currently being explored, as it may af-
fect the development of obesity [19]. SCFAs are also 
signalling molecules. Propionic, acetic and butyric 
acids are ligands for receptors coupled to G proteins, 
GPR41 and GPR43, belonging to a group of cell recep-
tors — G-protein coupled receptors (GPCRs). Both are 
epithelial receptors. Some studies suggest that GPR41 
controls energy balance of the body via the interaction 
with metabolites produced by the microflora. GPR43 
is proposed as a “molecular connector” between diet, 
gut microflora, immunity and inflammatory response. 
It was shown that mice lacking GPR41 and GPR43 have 
lower weight than their wild-type animals [16]. 
Butyric acid-dependent stimulation of leptin pro-
duction in adipocytes and induction of glucagon-like 
peptide 1 (GLP-1) secretion by the intestinal L cells [30] 
as well as increase in thermogenesis, fatty acid oxida-
tion and mitochondrial activity within the muscle and 
brown adipose tissue [31] are other examples of the 
impact of SCFAs on the metabolism of the host.
SCFAs’ roles are, however, diverse and they depend 
on existing conditions. Butyric acid may exhibit anti-
inflammatory activity, reducing the release of cytokines 
and chemokines [30]. In a study on obese mice fed 
with a high-fat diet enriched with butyrate, reduction 
and even normalization of insulin resistance was ob-
served [31]. Another study showed that eating a diet 
low in carbohydrates results in reduced concentration 
of butyric acid in stool samples and a decrease in the 
number of bacteria responsible for its production 
[32]. Based on this findings, it can be hypothesized 
that butyrate has a positive effect on metabolism in 
pathological states, but does not play a major role in 
normal conditions [12]. 
A mechanism promoting the development of obe-
sity and fat storage is reduced expression of fasting-
induced adipocyte factor (FIAF). FIAF, also known as 
angiopoietin-like protein 4, inhibits the lipoprotein 
lipase (LPL), an enzyme responsible for the storage of 
energy as fat. Since FIAF facilitates the release of fatty 
acids from lipoprotein triglycerides, reduced expres-
sion of FIAF is associated with higher LPL activity in 
adipocytes and increased energy storage.
The intestinal microflora may also affect lipid me-
tabolism of the host by inhibiting adenosine monophos-
phate-activated protein kinase (AMPK) [33]. AMPK is an 
enzyme that controls energy status at the cellular level 
[34]. “Germ-free” (GF) mice (the mice of sterile environ-
ment), even when fed with Western diet containing high 
amounts of sugar and fat, are protected against obesity. 
This is possible due to the high activity of the phospho-
rylated form of AMPK in the liver and skeletal muscles 
of these animals, and thereby high-efficiency oxidation 
of fatty acids in these two organs [33]. Active AMPK 
phosphorylates acetyl-CoA carboxylase, which leads 
to a decrease of malonyl-CoA. The compound inhibits 
carnitine palmitoyltransferase, an enzyme involved in the 
transfer of long-chain fatty acids into the mitochondria. 
This activates the process of fatty acids’ oxidation [16].
Bile acids
It has been found that the intestinal microflora 
affects the bile acid synthesis and metabolism. Bile 
acids can activate signalling pathways by both nuclear 
receptors and previously described GPCRs, the recep-
tors present on the cell surface. Farnesoid X receptor 
(FXR) was the first identified nuclear receptor that is 
activated by bile acids. In the blood of mice lacking this 
receptor (FXR–/–) elevated levels of triglycerides and 
glucose have been observed. This indicates that it may 
be involved in glucose and lipid metabolic pathways 
[35, 36]. Activation by bile acids of TGR5 membrane 
receptor that is expressed in in the brown adipose 
tissue and large intestine results in increased energy 
utilization in these tissues [37], and thus might prevent 
insulin resistance and obesity.
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Changes in intestinal microflora  
associated with obesity
Studies on germ-free mice that underwent 
transplantation of intestinal bacteria from obese or 
normal-weight mice showed an association between 
obesity and intestinal microflora. It was observed that, 
although both groups were fed with the same diet, GF 
mice that receive the microflora from mice with excess 
body weight also became obese [38]. Observations 
of people in a homogenous population who, despite 
the use of similar diets were more or less likely to gain 
weight and develop metabolic disorders, suggested the 
possible association of the intestinal microbiota with 
the aetiology of obesity [39, 40]. The predominance 
of two types of bacteria and, more specifically, their 
proportions were reported repeatedly in the conclu-
sions of many studies.
In obese subjects Bacterioidetes and Firmicutes 
ratio was shifted in favour of Firmicutes. Weight re-
duction was associated with proportional increase in 
the number of Bacterioidetes [41]. It has been proven 
that the increase in the number of Firmicutes by 20% 
and a similar decrease in the number of Bacteroidetes 
results in the raise in the amount of energy obtained 
from the food by 150 kcal [42]. Furthermore, research-
ers found the increase in the number of Bacteroides as 
a result of bariatric surgery (Roux-en-Y gastric bypass, 
RYGB) leading to weight loss in obese people. On the 
other hand, it should be mentioned once again that 
not all research supports such significant role of the 
intestinal microbiota in the pathogenesis of obesity. 
Some publications report the lack of correlation of the 
number of Bacterioidetes and Firmicutes with body 
weight [26]. It is not entirely clear whether changes 
in the microbiota in obese subjects are the result or 
the cause of obesity and certainly further studies are 
needed. In another experiment, the researchers com-
pared genetically modified, leptin-deficient obese mice 
(ob/ob) and lean mice (ob/+ and +/+) [43]. Leptin 
was chosen as a differentiating parameter, because it 
controls the appetite [44]. It has been shown that the 
microorganisms inhabiting the intestines of ob/ob mice 
have enzymes that enable degradation of otherwise 
indigestible polysaccharides contained in the food. 
Analyses of stools samples from obese individuals have 
also demonstrated a higher amount of final product 
of fermentation, such as acetic and butyric acids, and 
lower calorie content. In addition, it was observed 
that mice that are prone to insulin resistance and 
steatohepatitis, the most common complications of 
obesity, had abnormal levels of metabolites associated 
with the changes of phosphatidylcholine in blood and 
urine. When feeding the mice with a high fat diet, their 
microflora begins to transform food-derived choline 
into hepatotoxic methylamine. Choline is necessary for 
the secretion of very low density lipoprotein (VLDL). 
VLDL is synthesized in the liver, and its main function 
is to transport lipids from the liver to fat tissue cells 
— adipocytes. Intestinal microflora may participate in 
the pathogenesis of insulin resistance and steatohepa-
titis by reducing the bioavailability of choline. It can 
also initiate lipid peroxidation in the host organism 
[45]. Another difference observed in the microflora of 
obese individuals is increased number of methanogenic 
bacteria, which remove the harmful excess of H2 from 
the environment and thereby improve fermentation 
processes performed by the bacteria [43].
Dysbiosis, obesity, insulin resistance and the 
development of type 2 diabetes are associated with 
chronic systemic inflammation within adipose tissue. 
Gram-negative bacteria include LPS (described above) 
and peptidoglycans of inflammatory properties. The 
colonization of germ-free mice with Escherichia coli 
results in increased infiltration of adipose tissue by 
macrophages and enhanced secretion of cytokines. A 
diet high in fat results in elevated levels of LPS in human 
serum [46, 47]. LPS enters the blood in chylomicrons 
or, according to another theory, as a result of increased 
permeability of the gut [48].
LPS molecules have an affinity for Toll-like receptor 
4 (TLR4). TLR4 is a pattern recognition receptor (PRR) 
that binds to molecules of microorganisms. These 
receptors belong to the innate immune system and 
their stimulation activates pro-inflammatory signalling 
cascade [49, 50].
The level of LPS, which is one of pathogen-associat-
ed molecular patterns (PAMPs), is constantly monitored 
by TLR4 [50]. In rats susceptible to the occurrence of 
obesity, increased intestinal permeability and elevated 
levels of LPS in the blood have been observed [16]. In-
creased intestinal permeability has been noted in mice 
fed with a high-fat diet [51]. To sum up, elevated PAMP 
level and activation of PRRs induce inflammation, which 
in turn is associated with the development of metabolic 
disorders, such as insulin resistance or diseases of the 
cardiovascular system.
Intestinal microflora in type 2 diabetes
A number of studies have been performed on the 
correlation between the composition of the intestinal 
microflora and type 2 diabetes (T2D). It is believed 
that both insulin resistance and dysfunction of insulin-
producing beta-cells arise from the interaction of 
many environmental and genetic factors. Also, some 
relationship was found between qualitative composi-
tion of intestinal microflora and T2D. A study including 
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30 obese people, of whom seven were suffering from 
T2D, showed that patients with diabetes had reduced 
number of Faecalibacterium prausnitzii — bacteria 
belonging to the phylum Firmicutes that are normally 
found in the intestinal microflora. The study group un-
derwent bariatric surgery, after which in patients with 
T2D the number of F. praustnitzii increased, but was still 
lower than in subjects without diabetes. At the same 
time, reduced glucose and insulin concentration, and 
glycated haemoglobin in the blood were also found, 
as well as improvement in insulin resistance with the 
estimation based on the test results of homeostasis 
model assessment of insulin resistance (HOMA-IR). In 
addition, a decrease in markers of inflammation, i.e. 
CRP and IL-6, was also recorded [52]. Another study 
performed by Larsen et al. also concerned the phylum 
of Firmicutes. The study included 36 male adults, both 
with normal weight and obese, of whom 18 subjects 
had type 2 diabetes. The analysis of intestinal microflora 
showed reduced proportions of the phylum Firmicutes 
and class Clostridia in diabetic patients. It was also 
noted that the ratio of Bacteroidetes to Firmicutes cor-
related with plasma glucose concentration, similarly as 
in the above-described experiment, but there was no 
relationship to BMI, which certainly requires further 
analysis [53]. Data about ratios of Bacteroidetes to 
Firmicutes, i.e. Gram-negative to Gram-positive bacte-
ria, in patients with both obesity and type 2 diabetes 
are not completely clear-cut; however, a positive cor-
relation has been shown in mice between the plasma 
concentration of lipopolysaccharide (LPS) and weight 
gain, triglyceride accumulation, insulin resistance and 
type 2 diabetes. LPS, above-described component of 
cell membranes of Gram-negative bacteria, may be 
involved in the development of inflammation associ-
ated with type 2 diabetes. The results of animal stud-
ies have been confirmed by measurements of plasma 
LPS in healthy subjects and in patients with type 2 
diabetes. It has been shown that lipopolysaccharide 
concentration was higher in diabetic patients than in 
healthy subjects. This association may suggest that 
LPS is involved in the pathogenesis of type 2 diabetes 
[54]. What is more, administration of polymyxin B to 
rats results in decreased plasma concentration of LPS 
and reduces the incidence of steatohepatitis and other 
above-mentioned diseases.
Do available data allow the development of specific 
concepts to support the treatment of obesity and dia-
betes by modifying microflora of the patient? Changes 
in the ecosystem of the gut as part of the therapy and 
prevention of obesity and type 2 diabetes? Although 
the exact role of microorganisms belonging to the intes-
tinal microflora is still under research, the information 
gathered so far allow for starting the research aimed 
at introducing changes within the intestinal ecosystem 
and using them as a part of the therapy. Currently 
available pharmacological tools include antimicrobials, 
prebiotics and probiotics. Targeted use of these drugs 
changes the composition of the intestinal microflora 
and is at least partially effective in the preventing or 
treating metabolic diseases.
Antimicrobial drugs
It has been shown that the antimicrobial therapy 
reduces morbidity and delays the onset of type 1 
diabetes (T1D). Brugman et al. conducted a study on 
rat models of T1D — BB-DP (Bio-breeding diabetes 
prone). The intestinal microflora of rats that did not 
develop T1D was characterized by a reduced content 
of Bacteroidetes. The researchers then analysed the 
effect of antibiotics on the incidence of T1D. Antibiotic 
treatment in BB-DP rats caused changes in the intestinal 
microflora and reduced the incidence of T1D or delayed 
the symptoms’ onset. These results suggest that intes-
tinal microflora may be involved in the pathogenesis of 
type 1 diabetes. Furthermore, factors that can modify 
the composition of the intestinal flora, e.g. analysed 
antibiotics, may be part of a therapeutic intervention 
[55]. Also in type 2 diabetes (ob/ob mice) antibiotic 
treatment (ampicillin and norfloxacin) resulted in a 
significant improvement in glucose tolerance. These 
animals had reduced concentration of triglycerides 
in the liver and LPS in the blood, as well as increased 
levels of glycogen in the liver and adiponectin in blood.
Prebiotics
Prebiotics are non-digestible compounds, such 
as inulin and fructooligosaccharides, that stimulate 
the growth and activity of the intestinal bacterial 
strains; they are also a source of energy for intestinal 
epithelial cells and probiotic bacteria of the gastroin-
testinal tract. They accelerate the growth of beneficial 
commensal microorganisms such as Lactobacillus and 
Bifidobacterium. Studies with oligofructose provided 
very interesting conclusions of practical value. The first 
study demonstrated that the oligofructose added to 
high-fat diet increases the levels of insulin, decreases 
blood glucose levels and reduces both the amount of 
energy obtained and weight gain. It should be noted 
that this was achieved by an increased concentration of 
incretins, intestinal hormones that influence postpran-
dial secretion of insulin by the beta-cells of pancreatic 
islets, and thus are indirectly involved in the regulation 
of appetite and body weight [56, 57]. Another study 
found a positive correlation between Bifidobacterium 
and improved glucose tolerance, insulin secretion in 
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response to increased blood glucose levels and nor-
malization of inflammatory factors [58].
Reduction of fat absorption was observed in in-
dividuals who consumed food with prebiotics [59]. It 
was also shown that administration of oligofructose 
resulted in earlier satiety after breakfast and dinner, and 
significantly mitigated hunger. The above-described 
relationships and observations seem to imply an im-
portant role of prebiotic supplementation and provide 
the background for further research on the use of 
these compounds to modify the intestinal microflora 
and, consequently, aid in the treatment of obesity, 
overweight and type 2 diabetes. In summary, prebiot-
ics biochemically reduce the activity of the intestinal 
endocannabinoid system, increasing the concentra-
tion of GLP-2 that stimulates the synthesis of proteins 
forming the tight junction (zonula occludens 1 and 2, 
occludin); increase the number of Lactobacillus and 
Bifidobacterium; contribute to improving the functions 
and integrity of the intestinal barrier; contribute to 
reduction of endotoxaemia; decrease proinflammatory 
cytokines; and reduce oxidative stress [60].
Probiotics
Probiotics, i.e. live bacteria which have a benefi-
cial effect on human health, provide a diverse, well-
functioning intestinal microflora, which guarantees 
optimal generation of energy from food and its storage 
in the body.
Administration of probiotics modulates intestinal 
flora by increasing the number of Bifidobacteria and 
Lactobacilli. This results in improved function and in-
tegrity of the intestinal barrier, which translates into 
a reduction of internal toxaemia and inflammatory 
response and, consequently, improvement in insulin 
sensitivity and glucose or lipid metabolism [61]. Effect 
of probiotics is strain-specific and their use should be 
preceded by relevant clinical trials. The most meta-
bolically efficient bacterial species include: Lactobacil-
lus salivarius, Lactobacillus paracasei, Lactobacillus 
reuteri, Lactobacillus plantarum, Lactobacillus gaseri, 
and Bifidobacterium lactis. So far, there were only two 
randomized clinical trials published that evaluated the 
efficacy of probiotics in the treatment of glucose in-
tolerance and/or diabetes [62] and visceral obesity and 
overweight [63]. The first study assessed the effect of 
administration of Lactobacillus acidophilus NCFM on 
insulin sensitivity and the response to LPS endotoxin in 
45 individuals with normal glucose metabolism or with 
impaired glucose tolerance or type 2 diabetes [62]. This 
double-blind, randomized, placebo-controlled study 
lasted 4 weeks. Administration of 1010 CFU of probiotic 
bacteria daily improved insulin sensitivity and did not 
affect systemic inflammatory response. The second 
study [63] assessed the effect of Lactobacillus gasseri 
SBT2055 (1010 CFU/day) on anthropometric param-
eters in 87 patients with a BMI of 24.2–37.0 kg/m2 and 
visceral obesity. The study lasted 12 weeks and met the 
requirements of evidence-based medicine (EBM). It was 
found that the administration of probiotic lowers body 
weight, BMI, waist circumference and hip circumfer-
ence and reduces visceral fat and subcutaneous tissue. 
Not without significance are also the form in which 
probiotic bacteria are administered. The best known 
probiotics’ carriers are dairy products (yoghurts). How-
ever, due to short expiration term and the requirement 
to store these products in the refrigerator, it is difficult 
to provide the optimum number of health-beneficial 
bacteria. It seems, therefore, that the optimal and safe 
form of administration of probiotics are freeze-dried 
products available in the form of capsules or sachets.
Intestinal microflora transplantation
This treatment method has gained a lot of interest 
of the medical community; however, due to hygienic, 
aesthetic and cultural aspects is less accepted by the 
patients. Very promising results of experimental studies 
on animals encouraged researchers to use intestinal 
microflora transplantation (IMT) in the treatment of 
metabolic disorders and obesity. So far, a single study 
demonstrated increased sensitivity to insulin in patients 
six weeks after IMT. The method consists of introducing 
the donor stool, after its homogenization or dilution, 
into the duodenum (in patients with metabolic dis-
eases) or into large intestine (in Clostridium infections) 
using endoscopic technique. The centres with the great-
est experience are the Centre for Digestive Diseases in 
Sydney (> 3000 transplantations) and the Academic 
Medical Centre in Amsterdam (> 200 transplantations). 
It should be emphasized that no serious adverse events 
were observed [64].
Summary
There is no doubt that intestinal bacteria play a very 
important role in the pathogenesis of obesity and type 2 
diabetes. However, application of this knowledge in 
clinical practice is still insufficient. It is obvious that by 
modulating microflora, we can favourably affect the 
metabolism. There are a number of tools available, 
including prebiotics, probiotics and antimicrobial drugs 
(such as rifaximin — an antibiotic widely used in gastro-
enterology). Furthermore, increasingly bold and more 
advanced attempts of microflora transplantation also 
seem to be a promising treatment method.
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